Lantern Pharma Inc. Announces Board and Executive Compensation Changes
Ticker: LTRN · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $189,600 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
Related Tickers: LTRN
TL;DR
Lantern Pharma (LTRN) filed an 8-K detailing director departures, new elections, and executive pay changes effective Jan 6, 2025.
AI Summary
Lantern Pharma Inc. announced on January 6, 2025, changes related to its board of directors and executive compensation. The filing indicates a departure of a director, the election of a new director, and updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the financial implications of these compensatory arrangements are outlined in the report.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty and signal potential strategic shifts, impacting investor confidence.
Key Players & Entities
- Lantern Pharma Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Principal Executive Offices
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the initial summary of the 8-K.
Who was elected to the board of directors?
The filing states that a new director was elected, but the name of the individual is not specified in the provided text.
What is the effective date of these changes?
The earliest event reported is dated January 6, 2025.
What specific compensatory arrangements were updated?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not elaborated in the provided text.
What is Lantern Pharma Inc.'s principal executive office address?
Lantern Pharma Inc.'s principal executive offices are located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-10 16:05:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value LTRN The Nasdaq Stock Mar
- $189,600 — just Dr. Bhatia's annual base salary to $189,600, with such adjustment to take effect wi
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-25-001685.txt ( ) — 206KB
- ltrn-20250106.xsd (EX-101.SCH) — 3KB
- ltrn-20250106_lab.xml (EX-101.LAB) — 33KB
- ltrn-20250106_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, Lantern Pharma Inc.'s (the "Company's) Board of Directors approved the amendment of the employment agreement, as amended (the "Employment Agreement") for Kishor G. Bhatia, Chief Scientific Officer, to (i) extend the term of the Employment Agreement until January 15, 2026, (ii) adjust the minimum hours devoted by Dr. Bhatia per week to the scientific, clinical and therapeutic development operations and affairs of the Company to 24 hours per week, and (iii) proportionately adjust Dr. Bhatia's annual base salary to $189,600, with such adjustment to take effect with the first pay period in January 2025. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lantern Pharma Inc., A Delaware Corporation Dated: January 10, 2025 By: /s/ David R. Margrave David R. Margrave, Chief Financial Officer 3